Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
- Resource Type
- journal article
- Authors
- Desai, Jayesh; Gan, Hui; Barrow, Catherine; Jameson, Michael; Atkinson, Victoria; Haydon, Andrew; Millward, Michael; Begbie, Stephen; Brown, Michael; Markman, Ben; Patterson, William; Hill, Andrew; Horvath, Lisa; Nagrial, Adnan; Richardson, Gary; Jackson, Christopher; Friedlander, Michael; Parente, Phillip; Tran, Ben; Wang, Lai
- Source
- Journal of Clinical Oncology; 7/1/2020, Vol. 38 Issue 19, p2140-2150, 13p
- Subject
- Language
- ISSN
- 0732183X